Drug Profile
Research programme: cancer immunotherapies - Sellas Life Sciences/Ayala Pharmaceuticals
Alternative Names: ADXS; WT1-Lm Product - Sellas Life SciecesLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Advaxis; Sellas Life Sciences Group
- Developer Ayala Pharmaceuticals; Sellas Life Sciences Group
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 04 Jul 2019 Discontinued - Preclinical for Cancer in USA (Parenteral) (Sellas Life Sciences Group pipeline, July 2019)
- 26 Feb 2018 Preclinical trials in Cancer in USA (Parenteral) (Sellas Life Sciences, February 2018)